DNMT3A and acute myeloid leukemia: DNMT3A mutations in AML have been shown to have an increased rate of disease recurrence and are strongly associated with poor prognosis, despite not added to the adverse risk classification in 2017 European Leukemia Network (ELN) risk stratification yet [13].